Predix Pharmaceuticals Obtains Special Protocol Assessment For PRX-00023 Pivotal Study In Anxiety; Also Initiates Phase Ib Clinical Trial For PRX-08066 In Pulmonary Arterial Hypertension

LEXINGTON, Mass. & RAMAT GAN, Israel--(BUSINESS WIRE)--Nov. 30, 2005--Predix Pharmaceuticals, a drug discovery and development company, announced today that under the Special Protocol Assessment process, it has reached final agreement with the United States Food and Drug Administration (FDA) on the design and statistical analysis plan of its first pivotal study for PRX-00023, its 5-HT1A agonist and lead product candidate, to treat generalized anxiety disorder (GAD). In addition, Predix announced continued progress on its pipeline of internally discovered product candidates with the initiation of a Phase Ib clinical trial of PRX-08066, the company's novel small-molecule 5-HT2B antagonist, in conditioned athletic adults with transient pulmonary artery hypertension induced by a low oxygen environment.